- Home
- UTI vs GERN Comparison
UTI vs GERN Comparison
Compare UTI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTI
- GERN
- Stock Information
- Founded
- UTI 1965
- GERN 1990
- Country
- UTI United States
- GERN United States
- Employees
- UTI N/A
- GERN N/A
- Industry
- UTI Other Consumer Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- UTI Real Estate
- GERN Health Care
- Exchange
- UTI Nasdaq
- GERN Nasdaq
- Market Cap
- UTI N/A
- GERN 1.5B
- IPO Year
- UTI 2003
- GERN 1996
- Fundamental
- Price
- UTI $25.36
- GERN $1.65
- Analyst Decision
- UTI Strong Buy
- GERN Buy
- Analyst Count
- UTI 6
- GERN 11
- Target Price
- UTI $31.17
- GERN $5.80
- AVG Volume (30 Days)
- UTI 809.2K
- GERN 14.9M
- Earning Date
- UTI 05-07-2025
- GERN 05-01-2025
- Dividend Yield
- UTI N/A
- GERN N/A
- EPS Growth
- UTI 238.04
- GERN N/A
- EPS
- UTI 0.97
- GERN N/A
- Revenue
- UTI $759,421,000.00
- GERN $76,994,000.00
- Revenue This Year
- UTI $12.22
- GERN $208.83
- Revenue Next Year
- UTI $8.42
- GERN $57.49
- P/E Ratio
- UTI $26.31
- GERN N/A
- Revenue Growth
- UTI 14.70
- GERN 32386.92
- 52 Week Low
- UTI $13.66
- GERN $1.46
- 52 Week High
- UTI $30.56
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- UTI 41.50
- GERN 34.01
- Support Level
- UTI $26.47
- GERN $1.63
- Resistance Level
- UTI $27.91
- GERN $1.89
- Average True Range (ATR)
- UTI 1.18
- GERN 0.11
- MACD
- UTI -0.11
- GERN 0.04
- Stochastic Oscillator
- UTI 4.87
- GERN 21.87
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.